神経バイオマーカーの世界市場レポート 2025年

神経バイオマーカーの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR13.7％で199億6,000万米ドルに成長します。予測期間の成長は、早期発見のためのバイオマーカー、バイオセンサー、ウェアラブルデバイス、世界ヘルスイニシアチブ、患者中心のアプローチに起因しています。予測期間の主な動向には、画像診断の技術革新、オミックス技術の急速な進歩、人工知能（AI）の統合、バイオマーカー検証における実世界のエビデンス、診断技術の進歩、産業界と研究機関の連携などがあります。

神経疾患の有病率の増加が予想されることから、神経バイオマーカー市場の成長が見込まれます。神経疾患は脳、脊髄、身体の神経系に影響を与えます。パーキンソン病などの神経変性疾患の場合、神経バイオマーカーは病理学的、生化学的、遺伝学的検査を通じて早期診断を提供する上で重要な役割を果たします。2022年12月現在、パーキンソン財団はパーキンソン病の新規診断件数の増加を報告しており、2021年には年間60,000件であったのに対し、2022年には90,000件に達しています。この急増は、増大する神経疾患の有病率に対処するための神経バイオマーカーの役割を強調しています。

統合失調症の罹患率の増加は、神経バイオマーカー市場の成長に貢献すると予想されます。統合失調症は重度の精神疾患であり、認知、感情、行動の症状が現れます。神経バイオマーカーは、早期発見、客観的な診断尺度、個別化された治療、主観的評価への依存の低減、障害の神経生物学的メカニズムの深い理解の可能性を提供します。2022年1月に世界保健機関（WHO）が発表したところによると、世界では約2,400万人、300人に1人（0.32％）が統合失調症を患っており、成人では222人に1人（0.4％）の割合です。この有病率は、統合失調症のような病態に対処するための神経バイオマーカーの重要性を強調しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界神経バイオマーカーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の神経バイオマーカー市場：成長率分析
• 世界の神経バイオマーカー市場の実績：規模と成長, 2019-2024
• 世界の神経バイオマーカー市場の予測：規模と成長, 2024-2029, 2034F
• 世界神経バイオマーカー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の神経バイオマーカー市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• プロテオミクスバイオマーカー
• ゲノミクスバイオマーカー
• メタボロミクスバイオマーカー
• イメージングバイオマーカー
• その他の製品
• 世界の神経バイオマーカー市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アルツハイマー病
• パーキンソン病
• ハンチントン病
• 統合失調症
• うつ
• 多発性硬化症
• 脊髄性筋萎縮症
• 世界の神経バイオマーカー市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院の検査室
• 臨床診断センター
• 調査機関
• その他のエンドユーザー
• 世界の神経バイオマーカー市場プロテオミクスバイオマーカーのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タンパク質バイオマーカー
• 抗体バイオマーカー
• 世界の神経バイオマーカー市場、ゲノミクスバイオマーカーのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• DNAバイオマーカー
• RNAバイオマーカー
• 世界の神経バイオマーカー市場、メタボロミクスバイオマーカーのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 代謝物バイオマーカー
• 脂質バイオマーカー
• 世界の神経バイオマーカー市場、イメージングバイオマーカーのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• MRIバイオマーカー
• PETスキャンバイオマーカー
• 世界の神経バイオマーカー市場、その他の製品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 神経炎症バイオマーカー
• 神経伝達物質バイオマーカー

第7章 地域別・国別分析

• 世界の神経バイオマーカー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の神経バイオマーカー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 神経バイオマーカー市場：競合情勢
• 神経バイオマーカー市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca Plc
• Abbott Laboratories
• Boehringer Ingelheim International GmbH
• Becton Dickinson and Company
• Agilent Technologies Inc.
• Grifols S.A.
• Eisai Co. Ltd.
• PerkinElmer Inc.
• Illumina Inc.
• Shimadzu Corporation
• Waters Corporation
• Bio-Rad Laboratories Inc.
• Mallinckrodt Plc
• Qiagen N.V.
• Luminex Corporation.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 神経バイオマーカー市場2029：新たな機会を提供する国
• 神経バイオマーカー市場2029：新たな機会を提供するセグメント
• 神経バイオマーカー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A neurological biomarker is a substance that offers objective and quantifiable information regarding the presence, progression, or characteristics of a neurological disorder or condition. These biomarkers play a crucial role in clinical practice, particularly during drug development.

The main categories of neurological biomarkers include proteomics biomarkers, genomics biomarkers, metabolomics biomarkers, imaging biomarkers, and others. Proteomics biomarkers specifically involve proteins or patterns of proteins that can be identified and monitored by analyzing proteins in bodily fluids. These biomarkers find applications in various neurological conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, depression, multiple sclerosis, and spinal muscular atrophy. They are utilized by hospital laboratories, clinical diagnostic centers, research organizations, and other relevant entities.

The neurological biomarkers research report is one of a series of new reports from The Business Research Company that provides neurological biomarkers market statistics, including the neurological biomarkers industry's global market size, regional shares, competitors with neurological biomarkers market share, detailed neurological biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the neurological biomarkers industry. This neurological biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurological biomarkers market size has grown rapidly in recent years. It will grow from $10.7 billion in 2024 to $11.96 billion in 2025 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to increasing prevalence of neurological disorders, aging population, drug development needs, increased funding for neurological research, personalized medicine

The neurological biomarkers market size is expected to see rapid growth in the next few years. It will grow to $19.96 billion in 2029 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to biomarkers for early detection, biosensors, wearable devices, global health initiatives, patient-centric approach. Major trends in the forecast period include technological innovation in imaging, rapid advances in omics technologies, integration of artificial intelligence (ai), real-world evidence in biomarker validation, advancements in diagnostic technologies, collaboration between industry and research institutions.

The anticipated rise in the prevalence of neurological diseases is poised to drive the growth of the neurological biomarker market. Neurological illnesses impact the brain, spinal cord, and the body's nervous system. In the case of neurodegenerative disorders such as Parkinson's disease, neurological biomarkers play a crucial role in providing early diagnoses through pathological, biochemical, and genetic testing. As of December 2022, the Parkinson's Foundation reported an increase in new diagnoses of Parkinson's disease, reaching 90,000 in 2022 compared to 60,000 per year in 2021. This surge underscores the role of neurological biomarkers in addressing the growing prevalence of neurological diseases.

The increasing incidence of schizophrenia is expected to contribute to the growth of the neurological biomarkers market. Schizophrenia, a severe mental health disorder, presents cognitive, emotional, and behavioral symptoms. Neurological biomarkers offer the potential for early detection, objective diagnostic measures, personalized treatment, reduced reliance on subjective assessments, and a deeper understanding of the disorder's neurobiological mechanisms. Globally, approximately 24 million people, or 1 in 300 individuals (0.32%), suffer from schizophrenia, with adults experiencing this at a rate of one in 222 (0.4%), as reported by the World Health Organization in January 2022. This prevalence underscores the significance of neurological biomarkers in addressing conditions such as schizophrenia.

Major companies are forging partnerships to enhance innovation and solidify their market positions. For instance, in July 2022, NeuroSense Therapeutics Ltd., an Israel-based company developing treatments for severe neurodegenerative diseases partnered with NeuraLight, an Israel-based company developing objective and sensitive biomarkers for neurological disorders. This collaboration is to identify oculometric indicators for Amyotrophic Lateral Sclerosis (ALS) through the application of AI (Artificial Intelligence) and ML (Machine Learning). The partnership, which comes after NeuraLight's $25 million Series A financing, is to enhance the discovery and application of ALS digital indicators in a parallel study. This will be the collaboration's first clinical trial. The partnership is centered on the application of oculometric digital indicators, which may allow for patient classification and boost clinical trial success rates. Such collaborations facilitate the advancement and commercialization of novel therapies by combining resources and expertise.

Major companies in the neurological biomarkers market are developing innovative products, including advanced biomarker blood tests. For instance, in July 2023, Quanterix Corporation, a US-based company that specializes in the development and commercialization of ultra-sensitive digital immunoassay platforms launched the LucentAD biomarker blood test. This test, analyzing p-Tau 181 levels, aids medical professionals in evaluating patients with cognitive symptoms indicative of Alzheimer's disease. The test is positioned as a diagnostic tool for adults undergoing assessment for Alzheimer's disease but is not intended for standalone screening or diagnosis, emphasizing the need for a comprehensive diagnostic approach.

In April 2024, GE HealthCare, a US-based medical technology firm, acquired MIM Software Inc. for an undisclosed amount. GE HealthCare aims to enhance precision care by integrating advanced imaging analytics and streamlining workflows, ultimately improving patient outcomes and clinician efficiency. This strategic move positions GE HealthCare to provide more personalized treatment solutions across various medical specialties. MIM Software Inc., also a US-based company, specializes in medical imaging software and offers advanced imaging solutions that improve the identification and analysis of neurological biomarkers, aiding in the more effective diagnosis and monitoring of neurological disorders.

Major companies operating in the neurological biomarkers market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Thermos Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Agilent Technologies Inc., Grifols S.A., Eisai Co. Ltd., PerkinElmer Inc., Illumina Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Mallinckrodt Plc, Qiagen N.V., Luminex Corporation, Siemens Healthineers, Olink Proteomics, Meso Scale Diagnostics, Quanterix Corp., Fujirebio, Cisbio Bioassays SAS, NeuroVision Imaging, Proteome Sciences Plc, Acumen Pharmaceuticals.

North America was the largest region in the neurological biomarkers market in 2024. The regions covered in the neurological biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the neurological biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The neurological biomarker market consists of sales of genetic testing kits, electroencephalography (EEG) devices, and biomarker assay kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurological Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurological biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurological biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neurological biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Proteomics Biomarker; Genomics Biomarker; Metabolomics Biomarker; Imaging Biomarker; Other Products
• 2) By Application: Alzheimer's Disease; Parkinson's Disease; Huntington's Disease; Schizophrenia; Depression; Multiple Sclerosis; Spinal Muscular Atrophy
• 3) By End-User: Hospital Laboratories; Clinical Diagnostic Centers; Research Organizations; Other End-Users
• Subsegments:
• 1) By Proteomics Biomarker: Protein Biomarkers; Antibody Biomarkers
• 2) By Genomics Biomarker: DNA Biomarkers; RNA Biomarkers
• 3) By Metabolomics Biomarker: Metabolite Biomarkers; Lipid Biomarkers
• 4) By Imaging Biomarker: MRI Biomarkers; PET Scan Biomarkers
• 5) By Other Products: Neuroinflammatory Biomarkers; Neurotransmitter Biomarkers
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Novartis AG; Thermos Fisher Scientific Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neurological Biomarkers Market Characteristics

3. Neurological Biomarkers Market Trends And Strategies

4. Neurological Biomarkers Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Neurological Biomarkers Growth Analysis And Strategic Analysis Framework

• 5.1. Global Neurological Biomarkers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Neurological Biomarkers Market Growth Rate Analysis
• 5.4. Global Neurological Biomarkers Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Neurological Biomarkers Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Neurological Biomarkers Total Addressable Market (TAM)

6. Neurological Biomarkers Market Segmentation

• 6.1. Global Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Proteomics Biomarker
• Genomics Biomarker
• Metabolomics Biomarker
• Imaging Biomarker
• Other Products
• 6.2. Global Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alzheimer's Disease
• Parkinson's Disease
• Huntington's Disease
• Schizophrenia
• Depression
• Multiple Sclerosis
• Spinal Muscular Atrophy
• 6.3. Global Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Laboratories
• Clinical Diagnostic Centers
• Research Organizations
• Other End-Users
• 6.4. Global Neurological Biomarkers Market, Sub-Segmentation Of Proteomics Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Protein Biomarkers
• Antibody Biomarkers
• 6.5. Global Neurological Biomarkers Market, Sub-Segmentation Of Genomics Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• DNA Biomarkers
• RNA Biomarkers
• 6.6. Global Neurological Biomarkers Market, Sub-Segmentation Of Metabolomics Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Metabolite Biomarkers
• Lipid Biomarkers
• 6.7. Global Neurological Biomarkers Market, Sub-Segmentation Of Imaging Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• MRI Biomarkers
• PET Scan Biomarkers
• 6.8. Global Neurological Biomarkers Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Neuroinflammatory Biomarkers
• Neurotransmitter Biomarkers

7. Neurological Biomarkers Market Regional And Country Analysis

• 7.1. Global Neurological Biomarkers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Neurological Biomarkers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurological Biomarkers Market

• 8.1. Asia-Pacific Neurological Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurological Biomarkers Market

• 9.1. China Neurological Biomarkers Market Overview
• 9.2. China Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurological Biomarkers Market

• 10.1. India Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurological Biomarkers Market

• 11.1. Japan Neurological Biomarkers Market Overview
• 11.2. Japan Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurological Biomarkers Market

• 12.1. Australia Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurological Biomarkers Market

• 13.1. Indonesia Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurological Biomarkers Market

• 14.1. South Korea Neurological Biomarkers Market Overview
• 14.2. South Korea Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurological Biomarkers Market

• 15.1. Western Europe Neurological Biomarkers Market Overview
• 15.2. Western Europe Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurological Biomarkers Market

• 16.1. UK Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurological Biomarkers Market

• 17.1. Germany Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurological Biomarkers Market

• 18.1. France Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurological Biomarkers Market

• 19.1. Italy Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurological Biomarkers Market

• 20.1. Spain Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurological Biomarkers Market

• 21.1. Eastern Europe Neurological Biomarkers Market Overview
• 21.2. Eastern Europe Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurological Biomarkers Market

• 22.1. Russia Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurological Biomarkers Market

• 23.1. North America Neurological Biomarkers Market Overview
• 23.2. North America Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurological Biomarkers Market

• 24.1. USA Neurological Biomarkers Market Overview
• 24.2. USA Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurological Biomarkers Market

• 25.1. Canada Neurological Biomarkers Market Overview
• 25.2. Canada Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurological Biomarkers Market

• 26.1. South America Neurological Biomarkers Market Overview
• 26.2. South America Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurological Biomarkers Market

• 27.1. Brazil Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurological Biomarkers Market

• 28.1. Middle East Neurological Biomarkers Market Overview
• 28.2. Middle East Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurological Biomarkers Market

• 29.1. Africa Neurological Biomarkers Market Overview
• 29.2. Africa Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurological Biomarkers Market Competitive Landscape And Company Profiles

• 30.1. Neurological Biomarkers Market Competitive Landscape
• 30.2. Neurological Biomarkers Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Neurological Biomarkers Market Other Major And Innovative Companies

• 31.1. AstraZeneca Plc
• 31.2. Abbott Laboratories
• 31.3. Boehringer Ingelheim International GmbH
• 31.4. Becton Dickinson and Company
• 31.5. Agilent Technologies Inc.
• 31.6. Grifols S.A.
• 31.7. Eisai Co. Ltd.
• 31.8. PerkinElmer Inc.
• 31.9. Illumina Inc.
• 31.10. Shimadzu Corporation
• 31.11. Waters Corporation
• 31.12. Bio-Rad Laboratories Inc.
• 31.13. Mallinckrodt Plc
• 31.14. Qiagen N.V.
• 31.15. Luminex Corporation.

32. Global Neurological Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurological Biomarkers Market

34. Recent Developments In The Neurological Biomarkers Market

35. Neurological Biomarkers Market High Potential Countries, Segments and Strategies

• 35.1 Neurological Biomarkers Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Neurological Biomarkers Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Neurological Biomarkers Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer